Iproteos has closed a round of funding valued at 1.5 million Euros, led by Caixa Capital Risc and with participation of Kinled Holding, a Hong Kong based investment company with offices in London, New York and Zurich, and the biotech ASCIL Biopharm.

This new capital injection will be used for the completion of the preclinical phase of the lead compound for CIAS treatment. The compound has demonstrated its efficacy as a cognition enhancer in in vivo tests. There is no current treatment for this condition, fact that increases the value of the new chemical entity discovered by Iproteos.

To read the complete Press release: Ndp Iproteos-Ronda 1.5M€_ eng.pdf

Iproteos is glad to welcome Caixa Capital Risc, Kinled Holding and ASCIL Biopharm into the team!

Source info in English: Iproteos

Subscribe to Directory
Write an Article

Highlight

3i closes second European CLO, Harvest V...

by 3i Group

3i Group plc (“3i” or “3i Group”), an international investor, ...

AM-Pharma Raises €116m [$133m] to Cond...

by Ysios Capital

Financing co-led by new investors LSP and Andera Partners, with partic...

Photos Stream